Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,933 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Familial Alzheimer Disease Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Brain Health Study: A Pragmatic, Patient-Centered Trial

NCT05905796
View directory record Official record
Conditions
Dementia, Alzheimer Disease
Interventions
Brain Health Assessment
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
1,261 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01209156
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F] PBR111
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Dose Response Study of Aerobic Exercise in Older Adults

NCT01129115
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Nonexercise control group, Aerobic Exercise Group 1, Aerobic Exercise Group 2, Aerobic Exercise Group 3
Behavioral
Lead sponsor
Jeff Burns, MD
Other
Eligibility
65 Years and older
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of PF-04360365 On ABETA In Patients With Alzheimer's Disease And Healthy Volunteers

NCT01005862
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04360365, Placebo
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Glendale, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 17, 2026, 6:32 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Retinal Imaging in Neurodegenerative Disease

NCT03233646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions
Retinal and Choroidal Imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Our Care Wishes - Dementia

NCT05033262
View directory record Official record
Conditions
Dementia, Alzheimer Disease, Memory Impairment
Interventions
Our Memory Care Wishes
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 17, 2026, 6:32 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

NCT05395624
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Interventions
18F-OP-801
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 17, 2026, 6:32 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

A Study of Alzheimer's Disease Using Magnetoencephalography (MEG) and the Synchronous Neural Interaction™ Test

NCT01322373
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Not listed
Lead sponsor
Orasi Medical, Inc.
Industry
Eligibility
20 Years to 92 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Minneapolis, Minnesota • Plymouth, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Oct 17, 2026, 6:32 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Development of Novel Measures for Alzheimer's Disease Prevention Trials

NCT03900273
View directory record Official record
Conditions
Healthy Participants
Interventions
No Practice Effects (NPE) cognitive battery, and Miami Computerized Functional Assessment Scale (CFAS), Preclinical Alzheimer's Cognitive Composite (PACC), Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-Cog), and Functional Assessment Questionnaire (FAQ)
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
60 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Manhasset, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2025 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Phase 2 Interventional

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

NCT00112073
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
bapineuzumab, placebo
Drug · Other
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
50 Years to 85 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
26
States / cities
Sun City, Arizona • Irvine, California • Los Alamitos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Phase 1 Interventional Results available

Tau Imaging in Professional Fighters

NCT02278354
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Phase 2 Interventional

Tricaprilin in Mild to Moderate Alzheimer's Disease

NCT00142805
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Tricaprilin, Placebo
Drug · Other
Lead sponsor
Cerecin
Industry
Eligibility
50 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
25
States / cities
Phoenix, Arizona • Cerritos, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease

NCT00322153
View directory record Official record
Conditions
Dementia of the Alzheimer's Type
Interventions
memantine ER, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Costa Mesa, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Oct 17, 2026, 6:32 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Apolipoprotein E (APOE) Genotype Effects on Triglycerides and Blood Flow in the Human Brain

NCT04692441
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Heavy Cream
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 17, 2026, 6:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Falls: A Marker of Preclinical AD

NCT04949529
View directory record Official record
Conditions
Fall, Alzheimer Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
355 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 17, 2026, 6:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

NCT04639050
View directory record Official record
Conditions
Alzheimers Disease
Interventions
RO7126209, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
15
States / cities
Atlantis, Florida • Clermont, Florida • Lady Lake, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

NCT03071224
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
[18F] MNI-946, [18F]Florbetapir
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 17, 2026, 6:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating Cerebrospinal Fluid Biomarkers in Alzheimer's, Progressive Supranuclear Palsy Subjects, and Controls

NCT01348061
View directory record Official record
Conditions
Alzheimer Disease, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
KineMed
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Glendale, California • Eatontown, New Jersey • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2014 · Synced Oct 17, 2026, 6:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Juice Plus Supplement Clinical Trial

NCT04656860
View directory record Official record
Conditions
Cognitive Impairment, Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Interventions
Juice Plus+
Dietary Supplement
Lead sponsor
University of Alabama, Tuscaloosa
Other
Eligibility
55 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
2
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Phase 4 Interventional Results available

Antipsychotic Discontinuation in Alzheimer's Disease

NCT00417482
View directory record Official record
Conditions
Alzheimer Disease, Psychotic Disorders, Agitation, Aggression
Interventions
risperidone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
50 Years to 95 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Tuscaloosa, Alabama • Los Angeles, California • Norwalk, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Phase 3 Interventional Results available

A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease

NCT05891496
View directory record Official record
Conditions
Alzheimers Disease
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
55 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Sun City, Arizona • Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

NCT02079246
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Idalopirdine 60 mg
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
1,463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2018 · Synced Oct 17, 2026, 6:32 AM EDT
Not yet recruiting Not applicable Interventional

Fareon Open Label Device Clinical Trial

NCT07600320
View directory record Official record
Conditions
Cognitive Dysfunction, Acquired Brain Injury, Traumatic Brain Injury
Interventions
Fareon device
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 17, 2026, 6:32 AM EDT
Completed Phase 2 Interventional

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

NCT00153010
View directory record Official record
Conditions
Alzheimer Disease
Interventions
NS 2330 (Tesofensine)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 85 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
80
States / cities
Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2013 · Synced Oct 17, 2026, 6:32 AM EDT